Claims for Patent: 9,644,206

Summary for Patent: 9,644,206

Title:	Transgenic plants modified for reduced cadmium transport, derivative products, and related methods
Abstract:	Various embodiments are directed to transgenic plants, including transgenic tobacco plants and derivative seeds, genetically modified to impede the transport of Cadmium (Cd) from the root system to aerial portions of transgenic plants by reducing the expression levels of HMA-related transporters. Various embodiments are directed to transgenic tobacco plants genetically modified to stably express a RNAi construct encoding RNAi polynucleotides that enable the degradation of endogenous NtHMA RNA variants. Reduced expression of NtHMA transporters in transgenic plants results in substantially reduced content of Cadmium (Cd) in the leaf lamina. Various consumable products that are substantially free or substantially reduced in Cd content can be produced by incorporating leaves derived from transgenic tobacco plants modified to reduce the expression of NtHMA transporters.
Inventor(s):	Kudithipudi; Chengalrayan (Midlothian, VA), Hayes; Alec J. (Chesterfield, VA), van der Hoeven; Rutger S. (Midlothian, VA)
Assignee:	Philip Morris USA Inc. (Richmond, VA)
Application Number:	14/479,864
Patent Claims:	1. An NtHMA RNAi construct that inhibits the expression of an NtHMA messenger RNA to which it corresponds, wherein the construct comprises a heterologous promoter and: (a) a first sequence having at least 95% sequence identity to a sequence selected from the group consisting of: exon 1 (SEQ ID NO: 5), a fragment of exon 1 (SEQ ID NO: 5), exon 2 (SEQ ID NO: 7), a fragment of exon 2 (SEQ ID NO: 7), exon 3 (SEQ ID NO: 9), a fragment of exon 3 (SEQ ID NO: 9), exon 4 (SEQ ID NO: 11), a fragment of exon 4 (SEQ ID NO: 11), exon 5 (SEQ ID NO: 13), a fragment of exon 5 (SEQ ID NO: 13), exon 6 (SEQ ID NO: 15), a fragment of exon 6 (SEQ ID NO: 15), exon 7 (SEQ ID NO: 17), a fragment of exon 7 (SEQ ID NO: 17), exon 8 (SEQ ID NO: 19), a fragment of exon 8 (SEQ ID NO: 19), exon 9 (SEQ ID NO: 21), a fragment of exon 9 (SEQ ID NO: 21), exon 10 (SEQ ID NO: 23), a fragment of exon 10 (SEQ ID NO:23), exon 11 (SEQ ID NO: 25), and a fragment of exon 11 (SEQ ID NO:25); (b) a second sequence having at least 95% sequence identity to a sequence selected from the group consisting of: intron 1 (SEQ ID NO: 4), a fragment of intron 1 (SEQ ID NO:4), intron 2 (SEQ ID NO: 6), a fragment of intron 2 (SEQ ID NO:6), intron 3 (SEQ ID NO: 8), a fragment of intron 3 (SEQ ID NO:8), intron 4 (SEQ ID NO: 10), a fragment of intron 4 (SEQ ID NO: 10), intron 5 (SEQ ID NO: 12), a fragment of intron 5 (SEQ ID NO: 12), intron 6 (SEQ ID NO: 14), a fragment of intron 6 (SEQ ID NO: 14), intron 7 (SEQ ID NO: 16), a fragment of intron 7 (SEQ ID NO: 16), intron 8 (SEQ ID NO: 18), a fragment of intron 8 (SEQ ID NO: 18), intron 9 (SEQ ID NO: 20), a fragment of intron 9 (SEQ ID NO: 20), intron 10 (SEQ ID NO: 22), a fragment of intron 10 (SEQ ID NO: 22), intron 11 (SEQ ID NO: 24), a fragment of intron 11 (SEQ ID NO: 24), intron 12 (SEQ ID NO: 26), and a fragment of intron 12 (SEQ ID NO: 26); and (c) a third sequence having at least 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NO: 27, a fragment of SEQ ID NO: 27, SEQ ID NO: 28, a fragment of SEQ ID NO: 28, SEQ ID NO: 29, a fragment of SEQ ID NO: 29, SEQ ID NO: 30, a fragment of SEQ ID NO: 30, SEQ ID NO: 31, a fragment of SEQ ID NO: 31, SEQ ID NO: 32, a fragment of SEQ ID NO: 32, SEQ ID NO: 33, a fragment of SEQ ID NO: 33, SEQ ID NO: 34, a fragment of SEQ ID NO: 34, SEQ ID NO: 35, a fragment of SEQ ID NO: 35, SEQ ID NO: 36, a fragment of SEQ ID NO: 36, SEQ ID NO: 37, and a fragment of SEQ ID NO: 37; wherein the third sequence is the reverse complementary sequence of the first sequence, wherein said fragments are at least 30 contiguous nucleotides of the respective SEQ ID NO; and wherein the second sequence is positioned between the first sequence and the third sequence, and the second sequence is operably-linked to the first sequence and to the third sequence. 2. An NtHMA RNAi construct capable of inhibiting the expression of an NtHMA messenger RNA to which it corresponds, wherein the construct comprises: a first sequence comprising SEQ ID NO:38, a second sequence comprising SEQ ID NO:39, and a third sequence comprising SEQ ID NO:40; wherein the second sequence is positioned between the first sequence and the third sequence, and the second sequence is operably-linked to the first sequence and to the third sequence. 3. An NtHMA RNAi construct capable of inhibiting the expression of an NtHMA messenger RNA to which it corresponds, wherein the construct comprises: a first sequence comprising SEQ ID NO:42, a second sequence comprising SEQ ID NO:43, and a third sequence comprising SEQ ID NO:44; wherein the second sequence is positioned between the first sequence and the third sequence, and the second sequence is operably-linked to the first sequence and to the third sequence. 4. An NtHMA RNAi construct that inhibits the expression of an NtHMA messenger RNA to which it corresponds, wherein the construct comprises a heterologous promoter and: (a) and (c); or (a) and (b) and (c), wherein (a) is a first sequence having at least 95% sequence identity to a sequence selected from the group consisting of: exon 1 (SEQ ID NO: 5), a fragment of exon 1 (SEQ ID NO: 5), exon 2 (SEQ ID NO: 7), a fragment of exon 2 (SEQ ID NO: 7), exon 3 (SEQ ID NO: 9), a fragment of exon 3 (SEQ ID NO: 9), exon 4 (SEQ ID NO: 11), a fragment of exon 4 (SEQ ID NO: 11), exon 5 (SEQ ID NO: 13), a fragment of exon 5 (SEQ ID NO:13), exon 6 (SEQ. ID NO:15), a fragment of exon 6 (SEQ ID NO:15), exon 7 (SEQ ID NO:17), a fragment of exon 7 (SEQ ID NO:17), exon 8 (SEQ ID NO:19), a fragment of exon 8 (SEQ ID NO:19), exon 9 (SEQ ID NO:2), a fragment of exon 9 (SEQ ID NO:21), exon 10 (SEQ ID NO:23), a fragment of exon 10 (SEQ ID NO:23), exon 11 (SEQ ID NO:25), and a fragment of exon 11 (SEQ ID NO:25); wherein (b) is a second sequence having at least 95% sequence identity to a sequence selected from the group consisting of: intron 1 (SEQ ID NO: 4), a fragment of intron 1 (SEQ ID NO: 4), intron 2 (SEQ ID NO: 6), a fragment of intron 2 (SEQ ID NO:6), intron 3 (SEQ ID NO: 8), a fragment of intron 3 (SEQ ID NO: 8), intron 4 (SEQ ID NO: 10), a fragment of intron 4 (SEQ ID NO: 10), intron 5 (SEQ ID NO:12), a fragment of intron 5 (SEQ ID NO: 12), intron 6 (SEQ ID NO:14), a fragment of intron 6 (SEQ ID NO: 14), intron 7 (SEQ ID NO:16), a fragment of intron 7 (SEQ ID NO:16), intron 8 (SEQ ID NO: 18), a fragment of intron 8 (SEQ ID NO: 18), intron 9 (SEQ ID NO: 20), a fragment of intron 9 (SEQ ID NO:20), intron 10 (SEQ ID NO: 22), a fragment of intron 10 (SEQ ID NO:22), intron 11 (SEQ ID NO: 24), a fragment of intron 11 (SEQ ID NO: 24), intron 12 (SEQ ID NO: 26), and a fragment of intron 12 (SEQ ID NO: 26); and wherein (c) is a third sequence having at least 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NO: 27, a fragment of SEQ ID NO: 27, SEQ ID NO: 28, a fragment of SEQ ID NO: 28, SEQ ID NO: 29, a fragment of SEQ ID NO: 29, SEQ ID NO: 30, a fragment of SEQ ID NO: 30, SEQ ID NO: 31, a fragment of SEQ ID NO: 31, SEQ ID NO: 32, a fragment of SEQ ID NO: 32, SEQ ID NO: 33, a fragment of SEQ ID NO: 33, SEQ ID NO: 34, a fragment of SEQ ID NO: 34, SEQ ID NO: 35, a fragment of SEQ ID NO: 35, SEQ ID NO: 36, a fragment of SEQ ID NO: 36, SEQ ID NO: 37, and a fragment of SEQ ID NO: 37; wherein the third sequence is the reverse complementary sequence of the first sequence, wherein said fragments are at least 30 contiguous nucleotides of the respective SEQ ID NO; and further wherein when said construct comprises (a) and (b) and (c), the second sequence is positioned between the first sequence and the third sequence, and the second sequence Is operably-linked to the first sequence and to the third sequence.

Details for Patent 9,644,206

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2027-12-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2027-12-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2027-12-13